Regulators warn against Ivermectin for COVID-19

03 Sep 2021

Karen Stephens

by Karen Stephens

Mystery man

The Therapeutic Goods Administration (TGA) and the US Food and Drug Administration (FDA) have warned against using Ivermectin to prevent or treat COVID-19. 

Ivermectin has long been used to treat parasites such as scabies and head lice in humans and animals; and has worked in vitro against some viruses. An Australian study in 2020 sparked widespread medical and public interest when it showed Ivermectin could inhibit COVID-19 virus replication within a cell. However, this study was in a laboratory, using monkey cells and a dose higher than ever given to humans. 

The promotion of Ivermectin via the internet has seen a surge in demand, with the TGA detecting an increase in its importation, and reportedly in the US a shortage of animal worming products and increases in poisoning related to Ivermectin. 

Ivermectin is not approved in Australia as an anti-viral treatment, so any prescription would be off label. The TGA states that the consensus view of major regulators and top-tier international medical journals is that there is not strong evidence for its efficacy and safety for treatment or prevention of COVID-19, and this conclusion is also drawn by a Cochrane Review, the National Prescribing Service (NPS), the Royal Australian College of General Practitioners (RACGP), and even the drug's manufacturer, Merck Sharp & Dohme (MSD). The National COVID-19 Clinical Evidence Taskforce does not recommend use of Ivermectin for COVID-19 treatment outside of clinical trials with appropriate ethical approval.

Not yet subscribed to receive our medico-legal blog? Scroll down to subscribe and stay connected.

This blog contains general information only. We recommend you contact your medical defence organisation or insurer when you require specific advice in relation to medico-legal matters.



My Career Journey with Dr Nick Coatsworth

Dr Nick Coatsworth is an expert in health policy, public administration and a practising infectious diseases physician. He held a national role in the Australian response to COVID-19 as Deputy Chief Medical Officer of Australia, becoming one of the most recognised medical spokespeople during the pandemic. Nick engaged the Australian community through a variety of media platforms most notably as the spearhead of the national COVID-19 vaccination campaign. Dr Micheal Gannon, Obstetrician & Gynaecologist, sits down with Dr Nick Coatsworth to discuss Nick's medical career journey, and what insights and advice he has for junior doctors. MDA National would like to acknowledge the contributions of MDA National staff, Members, friends and colleagues in the production of the podcast and note that this work is copyright. Apart from any use permitted under applicable copyright law, you may not reproduce the content of this podcast without the permission of MDA National. This podcast contains generic information only, is intended to stimulate thought and discussion, and doesn’t account for requirements of any particular individual. The content may contain opinions which are not necessarily those of MDA National. We recommend that you always contact your indemnity provider when you require specific advice in relation to your insurance policy or medico-legal matters. MDA National Members need to contact us for specific medico-legal advice on freecall 1800 011 255 or email We may also refer you to other professional services.


09 Jun 2022

Career complications and contending with uncertainty

Among the many challenges of the COVID-19 pandemic for junior doctors is how to respond to medical training impacts and career uncertainty. In this podcast, Dr Caroline Elton (a psychologist who specialises in helping doctors)and Dr Benjamin Veness (a Psychiatry registrar) share advice for coping with medical training and career delays, disruptions and unknowns.


10 Aug 2020